# Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma

> **NCT03409848** · PHASE2 · COMPLETED · sponsor: **AIO-Studien-gGmbH** · enrollment: 97 (actual)

## Conditions studied

- Gastric Cancer
- Esophageal Cancer
- Adenocarcinoma Gastric
- HER2 Positive Gastric Cancer
- Metastatic Gastric Cancer
- GastroEsophageal Cancer

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT03409848
- **Lead sponsor:** AIO-Studien-gGmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-01
- **Primary completion:** 2022-03-05
- **Final completion:** 2022-03-05
- **Target enrollment:** 97 (ACTUAL)
- **Last updated:** 2022-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03409848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03409848, "Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03409848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*